Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 19/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429961 | 1.00 | EGFR (0.48) | EGFRMAPK14MAPK10MAPK13MAPK12 | |
| SCHEMBL26965255 | 0.91 | EGFR (0.51) | EGFRMAPK14MAPK10MAPK13MAPK12 | |
| SCHEMBL29429976 | 0.91 | EGFR (0.51) | EGFRMAPK14MAPK10MAPK13MAPK12 | |
| SCHEMBL26965289 | 0.87 | MAPK14 (0.52) | MAPK14MAPK10MAPK13MAPK12MAPK11 | |
| SCHEMBL29429873 | 0.87 | MAPK14 (0.52) | MAPK14MAPK10MAPK13MAPK12MAPK11 | |
| SCHEMBL29429929 | 0.86 | MAPK14 (0.56) | MAPK14MAPK10MAPK13MAPK12MAPK11 | |
| SCHEMBL26965158 | 0.86 | MAPK14 (0.56) | MAPK14MAPK10MAPK13MAPK12MAPK11 | |
| SCHEMBL26965202 | 0.84 | MAPK14 (0.54) | MAPK14MAPK10MAPK13MAPK12MAPK11 | |
| SCHEMBL29429891 | 0.84 | MAPK14 (0.54) | MAPK14MAPK10MAPK13MAPK12MAPK11 | |
| SCHEMBL26965216 | 0.84 | MAPK14 (0.54) | MAPK14MAPK10MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406838-A1 | MUTANT SELECTIVE EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406838-A1 | MUTANT SELECTIVE EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | EGFR 1/4885MAPK14 272/4885MAPK10 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.